{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039822","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.367211+00:00","generated_at":"2026-06-12T02:35:13.110643+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relay Therapeutics Q2 net loss $98.5M; RLY-2608 dose expansion initiated with 86% CBR","bullets":["Net loss of $98.5M ($0.81/share) in Q2 2023, up from $76.8M loss ($0.71) in Q2 2022; R&D expenses rose to $88.2M.","Cash and investments $871.6M as of June 30, 2023; expected to fund operations into H2 2025.","Initiated RLY-2608 600mg BID + fulvestrant dose expansion; interim CBR 86% (6/7 evaluable pts) with 1 partial response.","No Grade 3+ hyperglycemia/diarrhea or AE-related discontinuations across 43 breast cancer patients; next data update in 2024.","Anticipated milestones: RLY-4008 pivotal cohort enrollment H2 2023, ERα degrader candidate nomination 2023, RLY-2139 start early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039822","json":"https://secwatch.observer/filing/0000950170-23-039822.json","markdown":"https://secwatch.observer/filing/0000950170-23-039822.md","text":"https://secwatch.observer/filing/0000950170-23-039822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/0000950170-23-039822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/rlay-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:35:13.110643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"133bc90b7c80fefa9f6ec34f8943974bcb02d56e","claim":"Relay Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $98.5 million, EPS net loss per share of $0.81.","evidence_excerpt":"Net loss was $98.5 million for the second quarter of 2023, or a net loss per share of $0.81","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017023039822/0000950170-23-039822-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"Net loss was $98.5 million"},{"label":"EPS","value":"net loss per share of $0.81"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}